Table 6

Comparison of drug sensitivity between two groups of cell lines
Compound Mean of drug p-value n Targets
sensitivity k
c1 l c2 m
paclitaxel 0.1366 -0.2790 0.0323 PLK1, AURKA, BUB1
hymenialdisine 0.0590 -0.1359 0.2529 CDK1
olomoucine 0.0665 -0.1405 0.2311 CDK1
mercaptopurine 0.1012 -0.2037 0.1134 STK38
tamoxifen citrate 0.1003 -0.2121 0.0976 PRKCH, PRKCI, PRKCZ
imatinib 0.0425 -0.0358 0.3791 PDGFRA
sunitinib 0.0243 -0.0132 0.4384 PDGFRA
sorafenib 0.0801 -0.1779 0.184 PDGFRA, RAF1
DDUG 0.0860 -0.1811 0.1218 CHEK2
choline 0.0390 -0.2779 0.1188 CHKA
rapamycin -0.1044 0.1784 0.8866 MTOR
everolimus 0.0095 0.1526 0.7188 MTOR
nocodazole -0.0636 0.0026 0.5937 PLK1, BUB1
cisplatin -0.1546 0.1984 0.9376 SRPK1
bryostatin -0.0218 0.0958 0.6602 PKC family
axitinib -0.0278 0.0589 0.6235 PDGFRA

k mean of standardized negative log(GI50) values (higher means indicate higher sensitivity).

l c1: The NCI60 cell lines with functional p53 mutations.

m c2: The NCI60 cell lines with non-functional p53 mutations or p53 wild-type.

n The one-sided t-test statistics (hypothesis of higher drug sensitivity in cell lines with functional p53 mutations).

Wang and Simon

Wang and Simon BMC Medical Genomics 2013 6:30   doi:10.1186/1755-8794-6-30

Open Data